jiayi-li23/proxann_data huggingface dataset:
Bill 113-S-136 — Health / R&D
Subject: Taxation

Ethical Stem Cell Research Tax Credit Act of 2013 - Amends the Internal Revenue Code to allow a tax credit for 30% of qualified stem cell research expenses paid or incurred in a taxable year. Defines "qualified stem cell research expenses" as expenses for carrying out basic and applied research to develop techniques for the isolation, derivation, production, testing, and human clinical use of stem cells that may result in improved understanding of or treatments for diseases and other adverse health conditions. Prohibits a tax credit for any research expenses that may involve: (1) the creation of a human embryo for research purposes; (2) the destruction of or discarding of, or risk of injury to, a human embryo; or (3) the use of any stem cell for prohibited purposes.
Bill 113-S-220 — Health / R&D
Subject: Foreign trade and international finance

Citrus Disease Research and Development Trust Fund Act of 2013 - Amends the Trade Act of 1974 to establish the Citrus Disease Research and Development Trust Fund, consisting of revenues from duties paid on imported citrus or citrus products, to support scientific research, technical assistance, and development activities to combat both domestic and invasive citrus diseases and pests harming the United States.

 Establishes the Citrus Disease Research and Development Trust Fund Advisory Board.

Makes Fund amounts available to the Secretary of Agriculture to develop a coordinated program of research and product development relating to: (1) scientific research of both domestic and invasive diseases and pests afflicting the citrus industry; and (2) support for the dissemination and commercialization of relevant information, techniques, and technologies discovered through Fund research or other research projects intended to solve problems caused by citrus production diseases and invasive pests.

Requires the President to notify certain congressional committees before entering into a trade agreement that could result in a decrease in the amount of: (1) duties paid on imported citrus or citrus products, and (2) funds transferred into the Fund.

Prescribes a formula for required estimated tax payments otherwise due in each of the quarters of 2018 from corporations with assets of at least $1 billion.

Amends the Consolidated Omnibus Budget Reconciliation Act of 1985 (COBRA) to extend certain customs users fees for the processing of merchandise entered into the United States between October 23, 2021, and November 6, 2021, and other specified customs users fees for merchandise entered between October 30, 2021, and November 13, 2021.
Bill 113-S-424 — Health / R&D
Subject: Health

National Pediatric Research Network Act of 2013 - Amends the Public Health Service Act to authorize the Director of the National Institutes of Health (NIH), in carrying out the Pediatric Research Initiative, to act through the Director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development to provide for the establishment of a National Pediatric Research Network.

Authorizes the Director of the Institute to award funding to public or private nonprofit entities for: (1) planning, establishing, or strengthening pediatric research consortia; and (2) providing basic operating support for such consortia, including to meet unmet needs for pediatric research through basic, clinical and behavioral translational research and the training of researchers in pediatric research techniques. Authorizes the Director of NIH to make awards for not more than 20 pediatric research consortia, which must be formed from a collaboration of cooperating institutions, coordinated by a lead institution, agree to disseminate scientific findings, and meet requirements prescribed by the Director of NIH. Allows such support to be for a period of five years, with additional extensions at the discretion of the Director of NIH.

Requires the Director of NIH to provide for the coordination of activities among the consortia and to require the periodic preparation and submission of reports on their activities. Requires each pediatric research consortium receiving an award to assist the Centers for Disease Control and Prevention (CDC) in the establishment or expansion of patient registries and other surveillance systems as appropriate and upon request by the CDC.

Requires the Director of NIH to ensure that an appropriate number of such awards are awarded to consortia that agree to: (1) focus primarily on pediatric rare diseases or conditions; and (2) conduct or coordinate multi-site clinical trials of therapies for, or approaches to, the prevention, diagnosis, or treatment of pediatric rare diseases or conditions.

Requires the Director of NIH to establish a data coordinating center to: (1) distribute such findings; (2) provide assistance in the design and conduct of collaborative research projects and the management, analysis, and storage of data associated with such projects; and (3) organize and conduct multi-site monitoring activities.

Requires the Director of NIH to: (1) require the data coordinating center to provide regular reports to the Director of NIH and the Commissioner of Food and Drugs (FDA) on research conducted by consortia, including information on enrollment in clinical trials and the allocation of resources with respect to such research; and (2) incorporate such information into NIH's biennial reports.
Bill 113-S-626 — Health / R&D
Subject: Health

Prize Fund for HIV/AIDS Act - Denies any person the exclusive right to manufacture, distribute, sell, or use in interstate commerce a qualifying treatment for HIV/AIDS, or to a manufacturing process for such a treatment, including the exclusive right to rely on health registration data or the 30-month stay-of-effectiveness period for Orange Book patents. Prescribes remuneration, in the form of prize payments from a Prize Fund for HIV/AIDS, in lieu of such market exclusivity.

Exempts from this elimination of exclusive rights any dual use product that is a qualifying treatment for HIV/AIDS which also has a significant use for other diseases, but only with respect to its use for other diseases. Applies the elimination of exclusive rights with respect to a qualifying HIV/AIDS treatment even in a dual use product.

Establishes the Prize Fund for HIV/AIDS. Requires the Secretary of Health and Human Services (HHS) to designate a Prize Fund Director to administer the Fund.

Directs the Prize Fund Director to award prize payments for medical innovation relating to a qualifying treatment for HIV/AIDS, or a new manufacturing process for such a treatment, to: (1) the first person to receive market clearance with respect to the drug or biological product; (2) the holder of the patent with respect to a manufacturing process; or (3) persons or communities that as an open source contribution openly shared knowledge, data, materials, and technology on a royalty-free and nondiscriminatory basis.

Allows the Prize Fund Director to authorize multiple nonprofit intermediaries to manage Fund payments to reward projects for: (1) interim research and development of new qualifying treatments for HIV/AIDS, or (2) open source dividend prizes.

Establishes an annual fee for health insurers to fund this Act.

Establishes the Donor Innovation Prize Fund to enable the Secretary to reward owners and developers of products that permit open competition for low-cost generic drugs for the treatment of HIV/AIDS in developing countries.
Bill 113-S-637 — Health / R&D
Subject: Health

Collaborative Academic Research Efforts for Tourette Syndrome Act of 2013 - Amends the Public Health Service Act to require the Director of the National Institutes of Health (NIH) to expand, intensify, and coordinate NIH programs and activities regarding Tourette syndrome.

Requires the Director to develop a system to collect data on Tourette syndrome, including epidemiological information regarding its incidence and prevalence in the United States, primary data, and data on the availability of medical and social services for individuals with Tourette syndrome and their families.

 Requires the Director to award grants and contracts to public or nonprofit private entities to pay costs of planning, establishing, improving, and providing basic operating support for between four and six centers of excellence in different regions of the United States to conduct basic and clinical research on Tourette syndrome.

Requires the Director to designate a portion of the amounts made available to carry out NIH programs and activities for a fiscal year to carry out programs and activities with respect to Tourette syndrome.
Bill 113-S-709 — Health / R&D
Subject: Health

Health Outcomes, Planning, and Education for Alzheimer's Act - Amends title XVIII (Medicare) of the Social Security Act to provide for comprehensive Alzheimer's disease diagnosis and services.
Bill 113-S-865 — Health / R&D
Subject: Health

Accelerating the End of Breast Cancer Act of 2013 - Establishes the Commission to Accelerate the End of Breast Cancer to help end breast cancer by January 1, 2020.

Directs the Commission to identify, recommend, and promote initiatives, partnerships, and research within the public and private sectors, basic and applied sciences, and epidemiology that can be turned into strategies to prevent breast cancer and breast cancer metastasis while giving priority to those that are: (1) not prioritized within the public sector, and (2) unlikely to be achieved by the private sector due to technical and financial uncertainty.

Requires the Commission to: (1) submit within six months to the President and to the relevant congressional committees a description of the Commission's strategic plan; (2) submit an annual report to the President, Congress, and the public; and (3) ensure that its activities are coordinated with, and do not duplicate the efforts of, programs and laboratories of other government agencies.

Directs the President to enter into an agreement with the Institute of Medicine to evaluate the Commission's progress.

Terminates the Commission on June 1, 2020.
Bill 113-S-1027 — Health / R&D
Subject: Health

Amends the Public Health Service Act to authorize the Secretary of Health and Human Services (HHS) to: (1) establish a working group made up of representatives from various Institutes and Centers within the National Institutes of Health (NIH) to update and streamline NIH rehabilitation research priorities, and (2) enter into interagency agreements relating to the coordination of rehabilitation research conducted by agencies outside of HHS.

Requires the Secretary to report to Congress on the feasibility of implementing the changes proposed in the Blue Ribbon Panel Recommendations on Rehabilitation Research.
Bill 113-S-1091 — Health / R&D
Subject: Government operations and politics

Directs the United States Postal Service (USPS) to issue and sell an Alzheimer's Disease Research Semipostal Stamp.

Requires proceeds from the sale of the stamp to be transferred to the National Institutes of Health.

Requires the stamp to be made available to the public for six years.
Bill 113-S-1223 — Health / R&D
Subject: Health

Cavernous Angioma Research Resource Act of 2013 - Amends the Public Health Service Act to require the Director of the National Institutes of Health (NIH), acting through the Director of the National Institute of Neurological Disorders and Stroke, to expand and intensify NIH programs regarding research and related activities concerning cavernous angioma. Authorizes grants and cooperative agreements to public or nonprofit private entities for such activities.

Authorizes the Director of NIH to: (1) conduct basic, clinical, and translational research on cavernous angioma; (2) identify and support the development of a clinical and research coordinating center with the potential of coordinating a multi-site clinical drug trial for cavernous angioma; and (3) identify and support the development of clinical and research participation centers with the potential to participate in such a trial.

Requires coordinating and participation centers to expand training programs for medical and allied health clinicians and scientists in clinical practice and research relevant to cavernous angioma.

Authorizes the Director to provide for the participation of NIH agencies in a consortium (to include at least one patient advocacy organization) to facilitate the exchange of information and increase the efficiency and effectiveness of the research effort.

Authorizes the Secretary of Health and Human Services (HHS) to award grants and cooperative agreements, including technical assistance, to public or nonprofit private entities for: (1) the collection, analysis, and reporting of data on cavernous angioma; and (2) epidemiological activities, including collecting and analyzing information on the number, incidence, correlates, and symptoms of cases and the clinical utility of specific practice patterns. Requires establishment of a national surveillance program as part of such activities.

Requires the Commissioner of Food and Drugs (FDA) to: (1) work with clinical centers, investigators, and advocates to support appropriate investigational new drug applications under the Federal Food, Drug, and Cosmetic Act in order to hasten the pace of clinical trials for cavernous angioma; and (2) where applicable in rare subpopulations of cavernous angioma requiring unique pharmacological intervention, including those with the Common Hispanic Mutation or CCM3 gene mutations, support appropriate requests for designations of orphan drugs.
Bill 113-S-1239 — Health / R&D
Subject: Health

Scleroderma Research and Awareness Act - Requires the Director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases to expand, intensify, and coordinate the Institute's activities with respect to scleroderma, with particular emphasis on: (1) research focused on the etiology of scleroderma and the development of new treatment options, (2) clinical research to evaluate new treatment options, (3) basic research on the relationship between scleroderma and secondary conditions, (4) establishment of scleroderma patient registries, and (5) support for training of new clinicians and investigators with expertise in scleroderma.

Directs the Secretary of Health and Human Services (HHS), acting through the Director of the Centers for Disease Control and Prevention (CDC), to carry out an educational campaign to increase public awareness of scleroderma.
Bill 113-S-1247 — Health / R&D
Subject: Health

Pediatric, Adolescent, and Young Adult Cancer Survivorship Research and Quality of Life Act of 2013 - Amends the Public Health Service Act to allow the Secretary of Health and Human Services (HHS) to make grants to eligible entities to establish pilot programs to develop, study, or evaluate model systems for monitoring and caring for childhood cancer survivors.

Authorizes the Secretary to convene a Workforce Development Collaborative on Medical and Psychosocial Care for Pediatric Cancer to establish a plan to meet specified objectives relating to medical and psychosocial care workforce development, including: (1) disseminating to health care educators information relevant to providing medical and psychosocial services to individuals with pediatric cancers, (2) adapting curricula for continuing education of the existing workforce, and (3) strengthening the emphasis on psychosocial health care in educational accreditation standards and professional licensing and certification.
Bill 113-S-1552 — Health / R&D
Subject: Health

Next Generation Research Act - Amends the Public Health Service Act to establish the Next Generation of Research Initiative in the Office of the Director of the National Institutes of Health (NIH) for coordination of all NIH policies and programs aimed at promoting and providing opportunities for new researchers.

Requires the Director to: (1) promote existing policies and programs to improve opportunities for new researchers; (2) develop or modify policies, including to strengthen mentorship programs and enhance diversity efforts; and (3) request the National Academy of Sciences, as part of the required studies concerning biomedical and behavioral research personnel, to conduct a comprehensive study and report on policies affecting the next generation of researchers.
Bill 113-S-2115 — Health / R&D
Subject: Health

American Cures Act - Establishes a Biomedical Research Fund to be administered by the Secretary of the Treasury to provide for an expanded and sustained national investment in biomedical research.

Requires amounts to be transferred from the Fund for each fiscal year to accounts related to the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), the Department of Defense (DOD) health program, and the medical and prosthetics research program of the Department of Veterans Affairs (VA) to ensure that funding for such programs and agencies does not fall below 105% of the level of funding provided for the preceding fiscal year and an additional amount to account for any increases in the Gross Domestic Product for the year involved.

Requires that amounts appropriated for each of such programs and agencies for a fiscal year be not be less than the amounts appropriated for FY2014. Authorizes and appropriates to the Fund such sums as necessary in each fiscal year to enable such transfers.

Amends the Balanced Budget and Emergency Deficit Control Act to exempt the Fund from any sequestration order issued under such Act.
Bill 113-S-2126 — Health / R&D
Subject: Health

Regenerative Medicine Promotion Act of 2014 - Requires the Comptroller General to submit to Congress a report identifying all ongoing federal programs and activities regarding regenerative medicine.

Directs the Secretary of Health and Human Services (HHS) to establish a Regenerative Medicine Coordinating Council, which shall:

 prepare a national strategy to support research into regenerative medicine and enable the development of drugs, biological products, medical devices, and biomaterials for use in regenerative medicine; develop national goals for regenerative medicine research and product development; prepare a plan specifying priorities for research into regenerative medicine; identify sources of funding for research into regenerative medicine and areas where such funding is inadequate or duplicative; make recommendations regarding federal policies to support development and marketing of regenerative medicine products; develop consensus standards regarding scientific issues critical to regulator approval of regenerative medicine products; and determine the need for establishing centers of excellence or consortia to further advance regenerative medicine. Directs the Council to: (1) adopt procedures to ensure the receipt of public input; and (2) submit an annual report on its activities to Congress, the Director of the National Institutes of Health (NIH), and the Commissioner of Food and Drugs (FDA).
Bill 113-S-2150 — Health / R&D
Subject: Commerce

Independent Innovator and Repurposing Act - Establishes procedures under which the term of an unexpired patent claiming a method of using a biological product shall be extended for five years from its original expiration date.

 Requires an application for such an extension to demonstrate that: (1) the patent was issued to an independent innovator, and (2) the owner of record is the independent innovator or a small business (with fewer than 500 employees and which is not affiliated with the holder of the marketing application approved under licensing requirements of the Public Health Service Act for the commercial marketing of such biological product) in which the independent innovator has an ownership interest.

Defines "independent innovator" as a person or entity that obtains a method of use patent for a biological product and is not, at the time of invention or patent filing, affiliated with the holder of an approved application for the commercial marketing of the product.
Bill 113-S-2192 — Health / R&D
Subject: Health

Alzheimer's Accountability Act of 2014 - Amends the National Alzheimer's Project Act to require the Director of the National Institutes of Health (NIH), for each fiscal year through FY2025, to submit to the President for review and transmittal to Congress, after reasonable opportunity for comment (but without change) by the Secretary of Health and Human Services (HHS) and the Advisory Council on Alzheimer's Research, Care, and Services, an annual budget estimate (including regarding personnel needs) for the NIH initiatives under the Act.
Bill 113-S-2658 — Health / R&D
Subject: Health

Accelerating Biomedical Research Act - Amends the Balanced Budget and Emergency Deficit Control Act of 1985 to require certain adjustments to discretionary spending limits in FY2015-FY2021 to accommodate increases in appropriations to the National Institutes of Health (NIH) at the Department of Health and Human Services (HHS).
Bill 113-S-2804 — Health / R&D
Subject: Health

Family Asthma Act - Amends the Public Health Service Act to require the Director of the Centers for Disease Control and Prevention (CDC) to collaborate with state and local health departments to: (1) conduct activities regarding asthma, including deterring the harmful consequences of uncontrolled asthma, and disseminating health education and information regarding prevention of asthma episodes and strategies for managing asthma; and (2) develop state plans incorporating public health responses to reduce the burden of asthma, particularly regarding disproportionately affected populations.

 Revises and expands requirements for asthma surveillance activities.

 Requires the Director to coordinate data collection activities to maximize the comparability of results.

Requires the Secretary of Health and Human Services (HHS) to submit an assessment of current activities related to asthma prevention, management and surveillance along with recommendations for the future direction of asthma activities.
Bill 113-S-2841 — Health / R&D
Subject: Health

Reducing Disparities Using Care Models and Education Act of 2014 - Requires the Secretary of Health and Human Services (HHS) to contract with the Institute of Medicine to study health disparities, existing programs and policies intended to reduce disparities, and priorities for, and expansion of, programs targeting disparities.

Requires the Secretary to develop guidelines for entities to develop and implement programs to reduce health disparities. Directs the Secretary to incorporate these guidelines into HHS activities.

Authorizes the Secretary to award grants for programs to reduce health disparities.

Requires the Innovation Center of the Centers for Medicare and Medicaid Services (CMS) to test a payment and service delivery model that includes incentives for reducing health disparities.
Bill 113-S-2851 — Health / R&D
Subject: Health

Collaborative Academic Research Efforts for Tourette Syndrome Act of 2014 - Amends the Public Health Service Act to require the Director of the National Institutes of Health (NIH) to expand, intensify, and coordinate NIH research on Tourette syndrome.

Requires the Director to develop a system to collect data on Tourette syndrome, including epidemiological information, primary data, and data on the availability of medical and social services for individuals with Tourette syndrome and their families.

 Requires the Director to award grants and contracts to public or nonprofit private entities to support four to six Collaborative Research Centers for Tourette Syndrome in different regions to conduct basic and clinical research on Tourette syndrome.

 Requires the Director to award grants for research on the full range of symptoms within the Tourette syndrome clinical spectrum and the efficacy of treatment options for particular patient subpopulations.

Requires the Director to designate a portion of the amounts made available to carry out NIH programs and activities for a fiscal year to carry out programs and activities with respect to Tourette syndrome.